Identification | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Name | Lincomycin | ||||||||||||||||||||||||||||||
Accession Number | DB01627 | ||||||||||||||||||||||||||||||
Type | small molecule | ||||||||||||||||||||||||||||||
Description | An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections. [PubChem] | ||||||||||||||||||||||||||||||
Structure |
|
||||||||||||||||||||||||||||||
Categories (*) | |||||||||||||||||||||||||||||||
Molecular Weight | 406.537 | ||||||||||||||||||||||||||||||
Groups | approved | ||||||||||||||||||||||||||||||
Monoisotopic Weight | 406.21375752 | ||||||||||||||||||||||||||||||
Pharmacology | |||||||||||||||||||||||||||||||
Indication | Lincomycin is an antibiotic used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections. | ||||||||||||||||||||||||||||||
Mechanism of action | Lincomycin inhibits protein synthesis in susceptible bacteria by binding to the 50 S subunits of bacterial ribosomes and preventing peptide bond formation upon transcription. It is usually considered bacteriostatic, but may be bactericidal in high concentrations or when used against highly susceptible organisms. | ||||||||||||||||||||||||||||||
Absorption | Rapidly absorbed from the gastrointestinal tract following oral administration. Approximately 20 to 30% absorbed orally in fasting state; absorption decreased when taken with food. | ||||||||||||||||||||||||||||||
Protein binding | Protein binding decreases with increased plasma concentrations. Range, 28 to 86% (average, 70 to 75%). Albumin is not thought to be the primary binding component. | ||||||||||||||||||||||||||||||
Biotransformation | Presumed hepatic, however metabolites have not been fully characterized. | ||||||||||||||||||||||||||||||
Route of elimination | Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 3 percent). Tissue level studies indicate that bile is an important route of excretion. | ||||||||||||||||||||||||||||||
Toxicity | Not Available | ||||||||||||||||||||||||||||||
Affected organisms |
|
||||||||||||||||||||||||||||||
Interactions | |||||||||||||||||||||||||||||||
Drug Interactions |
|
||||||||||||||||||||||||||||||
Food Interactions |
|
50S ribosomal protein L10 | |
---|---|
Name | 50S ribosomal protein L10 |
Gene Name | rplJ |
Pharmacological action | yes |
Actions | inhibitor |
References |
|
DTHybrid score | 0.677 |
Id | Partner name | Gene Name | Score |
---|---|---|---|
4512 | Cytochrome P450 3A4 | CYP3A4 | 0.0962 |
4237 | 50S ribosomal protein L22 | rplV | 0.0918 |
4200 | Cytochrome P450 1A2 | CYP1A2 | 0.0316 |
1588 | Multidrug resistance protein 1 | ABCB1 | 0.0304 |
6030 | Cytochrome P450 2B6 | CYP2B6 | 0.0221 |
6143 | Solute carrier family 22 member 7 | SLC22A7 | 0.0176 |
6107 | Cytochrome P450 3A7 | CYP3A7 | 0.014 |
4118 | Cytochrome P450 3A5 | CYP3A5 | 0.0132 |
6016 | Cytochrome P450 2C19 | CYP2C19 | 0.0124 |